MarginsXMarginsX
Home › Markets › Health Care › ARTV

Artiva Biotherapeutics Inc. (ARTV)

ARTV trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.96
-1.25% on the day
Market cap
$195.8M
Micro cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$83.9M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/0001193125-26-100135-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerARTV on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2024
SEC CIK0001817241
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$83.9M
Operating income-$89.8M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$26.7M
Total assets$130.9M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
8.7 months
$61.2M cash at September 30, 2026
Share count, 1 year
+101.4%
2025-10-31 to 2026-10-30
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$32.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$61.2M cash; operating cash flow -$21.1M a quarter.Report 2026-09-30
Shares outstanding49,432,351 (2026-10-30); 24,544,904 a year earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-05-08
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $34.2M, sold $1.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$28.8M-$28.4M$61.2MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$25.0M-$20.4M$301.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$23.5M-$20.9M$21.0MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
Not filed-$20.8M-$14.7M$26.7MNo debt tags$010-K 2026-03-10
Q3 2025
2025-09-30
Not filed-$21.5M-$19.2M$25.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
Not filed-$21.3M-$23.0M$28.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2025
2025-03-31
Not filed-$20.3M-$19.8M$30.4MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
$0-$16.1M-$14.7M$40.2MNo debt tags$251K10-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-08-06
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K/A2026-11-09
Latest proxyDEF 14A2026-08-03

Source: SEC EDGAR submissions feed, 234 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.4%
1 month-36.2%
3 months-64.5%
Year to date-6.5%
1 year+18.3%
From 52-week high-70.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CGENCompugen Ltd.$2.04-2.86%$193.0M
LCTXLineage Cell Therapeutics Inc.$0.7951-13.07%$201.1M
IKTInhibikase Therapeutics Inc.$1.45-4.61%$203.4M
PALIPalisade Bio Inc.$1.03-8.04%$184.7M
CABACabaletta Bio Inc.$1.11-13.28%$239.4M
IVVDInvivyd Inc.$0.5377-7.63%$158.5M
IPHAInnate Pharma S.A. ADS$1.41-1.06%$156.9M
STROSutro Biopharma Inc.$9.32-5.09%$154.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier